View abstract

Cet abstract a été assigné à session FAB: Fluorescein Angiography Club Belgium
TitreContribution of intravitreal bevacizumab in macular edema due to central retinal vein occlusion (CRVO).
ButTo evaluate the effects of intravitreal bevacizumab on visual acuity and central macular thickness in eyes with macular edema due to central retinal vein occlusions (CRVO).
MéthodesThis retrospective study was conducted on patients having macular edema due to CRVO and treated with IVT bevacizumab between January 2006 and March 2011, in our hospital. All patients underwent visual acuity measurement, optical coherence tomography imaging, and ophthalmoscopic examination at baseline and follow-up visits.
Résultats31 eyes of 31 patients were included in the study (mean age 68 years, follow-up between 5 and 24 months). Initial mean visual acuity was 0.8 LogMAR. At 5, 12, and 18 months of follow-up, mean visual acuity improved respectively to 0.58 LogMAR (n = 31, p = 0.0125), 0.44 LogMAR (n = 18, p = 0.0092), and 0.64 LogMAR (n = 12, p = 0.6407). The mean central macular thickness at baseline was 664 μm. At 5, 12, 18 and 24 months of follow-up, mean central macular thickness had decreased respectively to 423 μm (n = 31, p = 0.0000), 424 μm (n = 18, p = 0.0008), 438 μm (n = 12, p = 0.050) and 420 μm (n = 7, p = 0.0216). No complications were recorded.

ConclusionThese encouraging results confirm the data of previous studies identifying IVT bevacizumab as a promising therapeutic option for macular edema due to OVCR.

Auteur 1
NomASSOULINE
InitialesJA
InstitutULB
VilleBruxelles
Auteur 2
NomCORDONNIER
InitialesMC
InstitutErasme
VilleBruxelles
Auteur 3
NomRASQUIN
InitialesF
InstitutErasme
VilleBruxelles
top ^